

Supplement No.2 (April 2015) ♦ Produced by The Central Prescribing Team

Prescribing Indicators 2015-16

The prescribing indicators for 2015-16 are broadly based on the National Therapeutic Indicators and the Additional Prescribing Measures. These were developed at the end of 2014 by a reference group of representatives from Health Boards across Scotland (including Lead CHCP/CHP Sector Pharmacists from NHS GGC).

Nationally prescribing indicators (known as National Therapeutic indicators (NTIs)) have

been developed for 4 years initially as part of the Quality and Efficiency Programme of the Scottish Government Directorate for Health and Social Care and more recently as part of the Therapeutics Branch of the Scottish Government's Quality Unit. These indicators cover core therapeutic areas including proton pump inhibitors, corticosteroids, hypnotics/anxiolytics, analgesics, antibiotics, antidiabetic drugs, non-steroidal anti-inflammatory drugs and antimicrobial wound management products.

Prescribing Indicators for 2015-16

GASTROINTESTINAL		
1	Proton Pump Inhibitors	DDDs per 1,000 weighted list size per day
CARDIOVASCULAR		
2	Lipid Regulating Drugs	Non-preferred list Lipid Regulating Drugs as a percentage of all lipid-regulating drugs (BNF 2.12) (items)
RESPIRATORY		
3	Corticosteroid Inhalers (High Strength)	High Strength Corticosteroid Inhalers as a percentage of all corticosteroid inhalers (items)*
CNS (PSYCHOTROPICS)		
4	Hypnotics and Anxiolytics	DDDs per 1,000 weighted list size per day
CNS (PAIN)		
5a	Opioid analgesics (Strong)	Strong opioids DDDs per 1,000 weighted list size per day
5b	Opioid analgesics (Step 2)	Step 2 Opioids other than strong opioids DDDs per 1,000 weighted list size per day
ANTIBIOTICS		
6a	Antibiotics (Total)	Total antibiotic script items per 1,000 list size per day
6b	Antibiotics (4C)	4C antibiotics script items per 1,000 list size per 100 days
7	Antimicrobial Wound Products	Antimicrobial wound products as percentage of total wound products (items)
DIABETES		
8	Antidiabetic Drugs (Metformin)	Metformin as percentage of all anti-diabetic drugs (DDDs)
MUSCULOSKELETAL, ANTI-INFLAMMATORIES & OSTEOPOROSIS		
9a	NSAIDs including Cox-2 inhibitors (Total)	DDDs per 1,000 weighted list size per day
9b	NSAIDs including Cox-2 inhibitors (Preferred)	Ibuprofen and naproxen as a percentage of all NSAIDs (DDDs)
URINARY FREQUENCY, URGENCY AND INCONTINENCE		
10	Antimuscarinics	DDDs per 1,000 weighted list size per day

*Fostair[®] excluded

Additional Prescribing Measures (APMs) complement the NTIs. Areas of analysis include patient safety measures (patient-level analysis of drug combinations that are known to increase the risk of adverse drug reactions), previous NTIs retained for use by some health boards, areas that compliment current NTIs and areas that are of interest but the measure is not sufficiently robust to have as an NTI.

Prescribing Measures for 2015-16

HIGH-RISK PRESCRIBING (EFIPPS MEASURES)		
11a	Aspirin/clopidogrel	Prescribing to people concurrently prescribed an oral anticoagulant without gastroprotection
11b	Antipsychotic	Prescribing to people aged ≥ 75 years
11c	NSAID	Prescribing to people aged ≥ 65 years concurrently prescribed an ACE inhibitor / angiotensin receptor blocker and a diuretic
11d	NSAID	Prescribing to people aged ≥ 75 years without gastroprotection
11e	NSAID	Prescribing to people aged ≥ 65 years concurrently prescribed aspirin / clopidogrel without gastroprotection
11f	NSAID	Prescribing to people concurrently prescribed an oral anticoagulant without gastroprotection
CARDIOVASCULAR		
12	NOACs	Items (dabigatran, apixaban and rivaroxaban) prescribed as a % of all items prescribed in BNF 2.8.2
RESPIRATORY		
13	Corticosteroid Inhalers (High Strength) in children	Under 12 years prescribed high strength corticosteroid inhalers as a % of all children prescribed inhaled corticosteroids
CNS (PAIN)		
14	Morphine	% of all morphine, oxycodone, fentanyl, tapentadol, and hydromorphone prescribed (DDDs)
15	Tramadol	DDDs/1000 weighted list size
16	Gabapentin	% of gabapentanoids (DDDs)
17	Pregabalin	DDDs/1000 weighted list size
18	Dihydrocodeine	DDD/1000 weighted list size
19	Lidocaine plasters	Cost/1000 weighted list size
DIABETES		
20	Self Monitoring of Blood Glucose	Cost of blood glucose test strips per patients treated for diabetes
		Number of patients prescribed insulin not prescribed SMBG as a % of all patients prescribed insulin
		People prescribed blood glucose test strips who are not prescribed treatments for diabetes (6.1.1 and/or 6.1.2) or are only prescribed metformin % of all people prescribed HBGM test strips
NEW MEDICINES		
21	Black triangle meds	% of all meds from BNF chapters 1-7 & 9-13 (items)

In addition to the NTIs and APMs developed nationally there are some locally agreed indicators (non-preferred list lipid regulating drugs antimuscarinics, pregabalin and lidocaine).

The baseline period for prescription data will be Oct-Dec 2014 to allow practices to agree prescribing actions in early 2015-16. Final achievement period will be Jan-Mar 2016 to allow practices the full year to complete prescribing actions.

GP practices will achieve the **prescribing indicator** if the shift in prescribing either:

- places them within the desired quartile of the baseline period

or

- is greater than 20% of the interquartile range of the baseline period and moving toward the desired quartile.

If the prescription data does not provide adequate evidence of change then GP practices will achieve the indicator if they submit a 5-point audit detailing the actions they have undertaken to achieve the agreed actions related to the prescribing indicator.

GP practices will achieve the **prescribing measure** if they submit a 5-point audit detailing the actions they have undertaken to achieve the agreed actions related to the prescribing measure.